Dry Eye and Inflammation of the Ocular Surface After Cataract Surgery: Effectiveness of a Tear Film Substitute Based on Trehalose/hyaluronic Acid Vs Hyaluronic Acid to Resolve Signs and Symptoms
Overview
Authors
Affiliations
Purpose: To compare the effect of trehalose 3%/hyaluronic acid 0.15% vs hyaluronic acid 0.15% eyedrops in reducing ocular surface inflammation after cataract surgery.
Setting: Perugia, Italy.
Design: Randomized, prospective study.
Methods: Patients with healthy ocular surface were enrolled. Tear break-up time (TBUT), Schirmer test, corneal fluorescein staining (CFS), ocular surface disease index (OSDI) and in vivo confocal microscopy (IVCM) were performed preoperatively and at 1 months, 4 months, and 8 months postoperatively. Patients were randomly assigned to receive trehalose 3%/hyaluronic acid 0.15% eyedrops (Group A), hyaluronic acid 0.15% eyedrops (Group B), or no treatment (Group C).
Results: 98 patients were randomized as follows: 33 in Group A, 33 in Group B, and 32 in Group C. Schirmer test increased at 1-month follow-up in Group A and unchanged in Groups B and C. TBUT and CFS increased at 1-month follow-up in Group A and after 8 months in Groups B and C. OSDI score decreased at 1-month follow-up in Group A and at in Groups B and C. IVCM showed a reduction in the number of nerve fibers of the subbasal nerve plexus at 1 month in all groups and progressively increased to preoperative levels at 4 months in Group A, and at 8 months in Groups B and C. Tortuosity and reflectivity of subbasal plexus progressively decreased to became significant at 4-month follow-up in Group A whereas increased at 1-month follow-up and become normal at 8-month follow-up in Groups B and C. Langerhans cells and activated stromal keratocytes were higher in Groups B and C throughout the follow-up with a significantly lower density of hyperreflective stromal cells in Group A.
Conclusions: Trehalose 3%/hyaluronic acid 0.15% eyedrops were effective in reducing inflammation and dry-eye symptoms.
Research progress of corneal characteristics and changes in primary angle‑closure glaucoma (Review).
Wang Y, Yan L, Qin Y, Fan F Biomed Rep. 2025; 22(4):59.
PMID: 39991004 PMC: 11843189. DOI: 10.3892/br.2025.1937.
Chen K, Chan H, Chan C Clin Ophthalmol. 2025; 19():19-33.
PMID: 39801566 PMC: 11721686. DOI: 10.2147/OPTH.S498869.
Lee C, Yang S, Chen H, Chang C Int J Med Sci. 2024; 21(15):2919-2925.
PMID: 39628696 PMC: 11610335. DOI: 10.7150/ijms.101341.
Mateo-Orobia A, Farrant S, Del-Prado-Sanz E, Blasco-Martinez A, Idoipe-Corta M, Lafuente-Ojeda N Ophthalmol Ther. 2024; 13(12):3123-3134.
PMID: 39432158 PMC: 11564544. DOI: 10.1007/s40123-024-01044-4.
Assessing the therapeutic role of trehalose and hyaluronic acid: implications for patient care.
Gawash A, Simonetti A, Lo D, Shamilov D, Kumar A, Wong J Int Ophthalmol. 2024; 44(1):398.
PMID: 39352586 DOI: 10.1007/s10792-024-03308-1.